Edition:
United Kingdom

Sienna Biopharmaceuticals Inc (SNNA.OQ)

SNNA.OQ on NASDAQ Stock Exchange Global Select Market

9.69USD
4:05pm GMT
Change (% chg)

$-0.09 (-0.92%)
Prev Close
$9.78
Open
$9.69
Day's High
$9.95
Day's Low
$9.69
Volume
1,936
Avg. Vol
17,419
52-wk High
$25.58
52-wk Low
$9.01

Latest Key Developments (Source: Significant Developments)

Sienna Biopharmaceuticals reports third quarter results
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS® REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.SIENNA BIOPHARMACEUTICALS INC - QTRLY NET LOSS PER SHARE $0.82.SIENNA BIOPHARMACEUTICALS INC - CASH AND CASH EQUIVALENTS AS OF SEPT. 30, 2018, TOTALED APPROXIMATELY $64.0 MILLION.  Full Article

Sienna Biopharmaceuticals Reports Results from Study of SNA-125 In Psoriasis
Monday, 27 Aug 2018 

Aug 27 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS ANNOUNCES RESULTS FROM FIRST-IN-HUMAN STUDY OF SNA-125 IN PSORIASIS AND CONTINUED PROGRESSION TO PHASE 2.SIENNA BIOPHARMACEUTICALS INC - SNA-125 PHASE 2 STUDIES EXPECTED TO BEGIN IN SECOND HALF OF 2019.SIENNA BIOPHARMACEUTICALS INC - SNA-125 PHASE 2 STUDIES EXPECTED TO BEGIN IN SECOND HALF OF 2019.SIENNA BIOPHARMACEUTICALS INC - PHASE 1/2 STUDY DATA OF SNA-125 IN ATOPIC DERMATITIS ON TRACK TO BE RELEASED IN Q4 OF 2018.SIENNA BIOPHARMACEUTICALS - IN MODEL, SNA-125 WAS WELL-TOLERATED AND SHOWED NO SAFETY SIGNALS.SIENNA BIOPHARMA - IN MODEL, ANALYSES SHOWED MODEST, STATISTICALLY SIGNIFICANT REDUCTION WITH SNA-125 0.2 PERCENT IN EPIDERMAL THICKNESS FROM BASELINE.  Full Article

Sienna Biopharmaceuticals May Offer And Sell Shares Of Co's Common Stock Having Offering Price Of Up To $75 Mln
Thursday, 23 Aug 2018 

Aug 23 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS-MAY OFFER AND SELL SHARES OF CO'S COMMON STOCK HAVING OFFERING PRICE OF UP TO $75 MILLION FROM TIME TO TIME .  Full Article

Sienna Biopharmaceuticals Reports Q2 Loss Per Share Of $1.00
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.SIENNA BIOPHARMACEUTICALS INC QTRLY LOSS PER SHARE $1.00.SIENNA BIOPHARMACEUTICALS INC - CASH BURN DURING THREE MONTHS ENDED JUNE 30, 2018, WAS APPROXIMATELY $15.8 MILLION.SIENNA BIOPHARMACEUTICALS INC - SIENNA'S CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2018, TOTALED APPROXIMATELY $74.9 MILLION.  Full Article

Sienna Biopharma Files For Mixed Shelf Of Upto $250 Mln
Friday, 3 Aug 2018 

Aug 3 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING.  Full Article

Sienna Completes Maximal Use Safety Study Of SNA-120 In Patients With Itch Associated With Psoriasis
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS SUCCESSFULLY COMPLETES MAXIMAL USE SAFETY STUDY OF SNA-120 IN PATIENTS WITH ITCH ASSOCIATED WITH PSORIASIS.SIENNA BIOPHARMACEUTICALS INC - PHASE 2B TOPLINE DATA EXPECTED IN Q1 OF 2019.SIENNA - NO DERMAL TOLERABILITY ISSUES, NO SUBJECT DISCONTINUATIONS DUE TO AE & NO SEVERE AES OR SERIOUS AES IN STUDY.SIENNA BIOPHARMACEUTICALS INC - SNA-120 WAS WELL TOLERATED WITH MINIMAL TO NO DETECTABLE SYSTEMIC EXPOSURE.  Full Article

Sebacia Announces Favorable Ruling By U.S. Court Regarding Patent Proceedings With Sienna Biopharma
Monday, 7 May 2018 

May 7 (Reuters) - Sebacia Inc::SEBACIA - ANNOUNCES FAVORABLE RULING BY U.S. FEDERAL COURT REGARDING PATENT INTERFERENCE PROCEEDINGS WITH SIENNA BIOPHARMACEUTICALS INC.SEBACIA - RULING RELATES TO PATENT INTERFERENCE PROCEEDING BETWEEN GENERAL HOSPITAL CORP, OWNER OF SOME OF CO'S LICENSED PATENTS, & SIENNA BIOPHARMACEUTICALS.SEBACIA SAYS FEDERAL CIRCUIT RULED IN FAVOR OF GHC REGARDING A PATENT INTERFERENCE PROCEEDING CONCERNING SIENNA'S PATENT NO. 8,812,941.  Full Article

Sienna Biopharmaceuticals Announces First Patient Dosed In Proof-Of-Concept Trial Of Topical By Design JAK Inhibitor SNA-125 For Atopic Dermatitis
Monday, 12 Mar 2018 

March 12 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PROOF-OF-CONCEPT TRIAL OF TOPICAL BY DESIGN™ JAK INHIBITOR SNA-125 FOR ATOPIC DERMATITIS.SIENNA BIOPHARMACEUTICALS INC - ‍TOP-LINE RESULTS FROM STUDY EXPECTED IN Q4 OF 2018​.SIENNA BIOPHARMACEUTICALS INC - ‍TRIAL TO ENROLL ABOUT 30 PATIENTS WITH ATOPIC DERMATITIS​.  Full Article

Sienna Biopharmaceuticals posts qtrly loss per share $1.12‍​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sienna Biopharmaceuticals Inc :Sienna Biopharmaceuticals reports third quarter 2017 financial results.Sienna Biopharmaceuticals Inc - Qtrly loss per share $1.12‍​.Sienna Biopharmaceuticals Inc - ‍Sienna's cash and cash equivalents as of Sept. 30, 2017, totaled approximately $88.6 million​.Sienna Biopharmaceuticals - ‍ Expects non-cash component related to acquisition of creabilis to continue to impact G&A expenses in future quarters​.  Full Article

Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Sienna Biopharmaceuticals Inc :Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120.Sienna Biopharmaceuticals Inc - ‍top-line results expected in first half of 2019​.Sienna Biopharmaceuticals - ‍phase 2B trial of topical SNA-120 to enroll about 190 patients with Pruritus associated with psoriasis​.  Full Article

UPDATE 2-Sienna Biopharma sinks after acne treatment fails two trials

* Shares hit record low (Adds details from conference call, updates share movement)